Chengheng Liao

Dr. Chengheng Liao

UT Southwestern Medical Center
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2018 in Science
Verified
Journal Article
Closed access
PDF file
JZJing Zhang
Jing Zhang
TWTao Wu
Tao Wu
JSJeremy Simon
Jeremy Simon
MTMamoru Takada
Mamoru Takada
RSRyoichi Saito
Ryoichi Saito
QZQING ZHANG
QING ZHANG
Mechanistic insights into kidney cancer: Many clear cell renal cell carcinomas (ccRCCs) have alterations to the gene encoding the von Hippel-Lindau protein (VHL). VHL is a ubiquitin ligase that degrades target proteins when they are prolyl-hydroxylated. Zhang et al. performed a genome-wide search for VHL target (see the Perspective by Sanchez and Simon). They identified ZHX2, a protein with structural motifs that indicate DNA binding. ZHX2 has been implicated in tumor suppression. Loss of ZHX2 inhibited signaling through the transcription factor NF-κB, and ZHX2 bound to many NF-κB target genes. Depletion of ZHX2 slowed growth of ccRCC cells in vitro and in a mouse model. Science , this issue p. 290 ; see also p. 226

19 March 2021 in Cells
Verified
Journal Article
Open access
PDF file
RSRachel Shi
Rachel Shi
Chengheng LiaoChengheng Liao
Chengheng Liao
QZQING ZHANG
QING ZHANG
Hypoxia, a common feature of solid tumors, greatly hinders the efficacy of conventional cancer treatments such as chemo-, radio-, and immunotherapy. The depletion of oxygen in proliferating and advanced tumors causes an array of genetic, transcriptional, and metabolic adaptations that promote survival, metastasis, and a clinically malignant phenotype. At the nexus of these interconnected pathways are hypoxia-inducible factors (HIFs) which orchestrate transcriptional responses under hypoxia. The following review summarizes current literature regarding effects of hypoxia on DNA repair, metastasis, epithelial-to-mesenchymal transition, the cancer stem cell phenotype, and therapy resistance. We also discuss mechanisms and pathways, such as HIF signaling, mitochondrial dynamics, exosomes, and the unfolded protein response, that contribute to hypoxia-induced phenotypic changes. Finally, novel therapeutics that target the hypoxic tumor microenvironment or interfere with hypoxia-induced pathways are reviewed.

2 May 2024 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
Chengheng LiaoChengheng Liao
Chengheng Liao
LHLianxin Hu
Lianxin Hu
QZQING ZHANG
QING ZHANG

1 March 2020 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
LHLianxin Hu
Lianxin Hu
HXHaibiao Xie
Haibiao Xie
XLXijuan Liu
Xijuan Liu
FPFrances Potjewyd
Frances Potjewyd
LJLindsey I. James
Lindsey I. James
QZQING ZHANG
QING ZHANG
TANK binding kinase 1 (TBK1) is an important kinase involved in the innate immune response. Here we discover that TBK1 is hyperactivated by von Hippel-Lindau (VHL) loss or hypoxia in cancer cells. Tumors from patients with kidney cancer with VHL loss display elevated TBK1 phosphorylation. Loss of TBK1 via genetic ablation, pharmacologic inhibition, or a new cereblon-based proteolysis targeting chimera specifically inhibits VHL-deficient kidney cancer cell growth, while leaving VHL wild-type cells intact. TBK1 depletion also significantly blunts kidney tumorigenesis in an orthotopic xenograft model in vivo. Mechanistically, TBK1 hydroxylation on Proline 48 triggers VHL as well as the phosphatase PPM1B binding that leads to decreased TBK1 phosphorylation. We identify that TBK1 phosphorylates p62/SQSTM1 on Ser366, which is essential for p62 stability and kidney cancer cell proliferation. Our results establish that TBK1, distinct from its role in innate immune signaling, is a synthetic lethal target in cancer with VHL loss. Significance: The mechanisms that lead to TBK1 activation in cancer and whether this activation is connected to its role in innate immunity remain unclear. Here, we discover that TBK1, distinct from its role in innate immunity, is activated by VHL loss or hypoxia in cancer. See related commentary by Bakouny and Barbie, p. 348. This article is highlighted in the In This Issue feature, p. 327

7 December 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
Chengheng LiaoChengheng Liao
Chengheng Liao
LYLili Yao
Lili Yao
YXYa Xu
Ya Xu
WLWei-Bing Liu
Wei-Bing Liu
YZYing Zhou
Ying Zhou
BYBang-Ce Ye
Bang-Ce Ye
The regulatory mechanisms underlying the uptake and utilization of multiple types of carbohydrates in actinomycetes remain poorly understood. In this study, we show that GlnR (central regulator of nitrogen metabolism) serves as a universal regulator of nitrogen metabolism and plays an important, previously unknown role in controlling the transport of non-phosphotransferase-system (PTS) carbon sources in actinomycetes. It was observed that GlnR can directly interact with the promoters of most (13 of 20) carbohydrate ATP-binding cassette (ABC) transporter loci and can activate the transcription of these genes in response to nitrogen availability in industrial, erythromycin-producing Saccharopolyspora erythraea. Deletion of the glnR gene resulted in severe growth retardation under the culture conditions used, with select ABC-transported carbohydrates (maltose, sorbitol, mannitol, cellobiose, trehalose, or mannose) used as the sole carbon source. Furthermore, we found that GlnR-mediated regulation of carbohydrate transport was highly conserved in actinomycetes. These results demonstrate that GlnR serves a role beyond nitrogen metabolism, mediating critical functions in carbon metabolism and crosstalk of nitrogen- and carbon-metabolism pathways in response to the nutritional states of cells. These findings provide insights into the molecular regulation of transport and metabolism of non-PTS carbohydrates and reveal potential applications for the cofermentation of biomass-derived sugars in the production of biofuels and bio-based chemicals. Significance Actinomycetes abundantly generate beneficial metabolic products. The efficient coutilization of heterogeneous carbon sources remains a major technical challenge for the industrial-scale production of drugs, chemicals, materials, and fuels by actinomycetes. Here, we present insights into the regulatory mechanisms of uptake and utilization of multiple carbohydrates in actinomycetes. GlnR (central regulator of nitrogen metabolism) was shown to regulate the control of ATP-binding cassette transport systems for secondary, non-phosphotransferase-system carbon sources. By integrating nitrogen signals to modulate the uptake and utilization of multiple carbon sources, GlnR mediates the interplay between nitrogen and carbon metabolism. These findings highlight the potential of actinomycetes in carbon utilization (especially cofermentation of biomass-derived sugars) for biorefinery applications. To our knowledge, our data represent the first systematic description of GlnR-mediated regulation of carbohydrate metabolism in actinomycetes.

20 July 2020 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
Chengheng LiaoChengheng Liao
Chengheng Liao
YZYang Zhang
Yang Zhang
CFCheng Fan
Cheng Fan
LHLaura E. Herring
Laura E. Herring
JLJuan Liu
Juan Liu
QZQING ZHANG
QING ZHANG
Triple-negative breast cancer (TNBC) is an aggressive and highly lethal disease. Because of its heterogeneity and lack of hormone receptors or HER2 expression, targeted therapy is limited. Here, by performing a functional siRNA screening for 2-OG–dependent enzymes, we identified gamma-butyrobetaine hydroxylase 1 (BBOX1) as an essential gene for TNBC tumorigenesis. BBOX1 depletion inhibits TNBC cell growth while not affecting normal breast cells. Mechanistically, BBOX1 binds with the calcium channel inositol-1,4,5-trisphosphate receptor type 3 (IP3R3) in an enzymatic-dependent manner and prevents its ubiquitination and proteasomal degradation. BBOX1 depletion suppresses IP3R3-mediated endoplasmic reticulum calcium release, therefore impairing calcium-dependent energy-generating processes including mitochondrial respiration and mTORC1-mediated glycolysis, which leads to apoptosis and impaired cell-cycle progression in TNBC cells. Therapeutically, genetic depletion or pharmacologic inhibition of BBOX1 inhibits TNBC tumor growth in vitro and in vivo. Our study highlights the importance of targeting the previously uncharacterized BBOX1–IP3R3–calcium oncogenic signaling axis in TNBC. Significance: We provide evidence from unbiased screens that BBOX1 is a potential therapeutic target in TNBC and that genetic knockdown or pharmacologic inhibition of BBOX1 leads to decreased TNBC cell fitness. This study lays the foundation for developing effective BBOX1 inhibitors for treatment of this lethal disease. This article is highlighted in the In This Issue feature, p. 1611